Recent progress in the management of endocrine tumors;Progrès récents dans la prise en charge des tumeurs endocrines

Medecine Therapeutique Endocrinologie

Volumn 3, Issue SPEC. ISS. SEPT., 2001, Pages 18-24

  Baudin, E ^a   Bachelot, A ^a   Ducreux, M ^a   Schlumberger, M ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; DOCETAXEL; IRINOTECAN; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

CARCINOID; DISEASE PREDISPOSITION; ENDOCRINE TUMOR; GENETIC PREDISPOSITION; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; NEUROENDOCRINE TUMOR; PROGNOSIS; REVIEW; TUMOR CLASSIFICATION;

EID: 29244435798     PISSN: 12959359     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Histological typing of endocrine tumors
2. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: Prognostic evaluation by pathological analysis
3. Prognostic criteria in nonfunctioning pancreatic endocrine tumours
4. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid
5. Aspects méthodologiques et intérêt clinique du dosage de la chromogranine A
6. Chromogranin A and the α subunit of glycoprotein hormones in medullary thyroid carcinoma and pheochromocytoma
7. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumors
8. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors
9. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by Zollinger-Ellison syndrome
10. Prospective study of somatostatin receptor scintigraphy and its effects on operative outcome in patients with Zollinger Ellison syndrome
11. Detection of small, functional islet cell tumors in the pancreas: Selection of MR imaging sequences for optimal sensitivity
12. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumors
13. Value of somatostatin receptor scintigraphy: A prospective study in gastrinoma of its effect on clinical management
14. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors
15. Specificity of somatostatin receptor scintigraphy: A prospective study and the effects of false positive localizations on management in patients with gastrinomas
16. Bone metastases in patients with gastrinomas: A prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management
17. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: Bone scintigraphy compared with somatostatin receptor scintigraphy
18. Value of peptide receptor scintigraphy using 123 I-vasoactive intestinal peptide and 111 In-DTPA-D-pheoctreotide in 194 carcinoid patients: Vienna university experience, 1993 to 1998
19. Metabolic (PET) and receptor (SPET) imaging of well and less well-differentiated tumors: Comparison with the expression of the Ki67 antigen
20. Positron emission tomography with 5 hydroxytryptophan in neuroendocrine tumors
21. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with longstanding Zollinger-Ellison syndrome
22. Surgery to cure the Zollinger-Ellison syndrome
23. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors
24. Prognostic factors in patients with endocrine tumors of the duodenopancreatic area
25. Pulmonary atypical carcinoid: Predictors of survival in 106 cases
26. Endocrine tumors of the pancreas: Ki67 immunoreactivity of paraffin sections is an independent predictor for malignancy: A comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables
27. Prognostic markers in patients with typical bronchial carcinoid tumors
28. Treatment of poorlydifferentiated neuroendocrine tumors with etoposide and cisplatin
29. Recent advances in systemic therapy for gastrointestinal neuroendocrine tumors
30. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome
31. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms
32. Antitumoral activity of somatostatin analog in progressive metastatic gastroenteropancreatic neuroendocrine tumors
33. Pre-clinical comparison of (DTPA°) octreotide, (DTPA°, Tyr3) octreotide and (DOTA°, Tyr3) octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionucleide therapy
34. A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors
35. Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrin tumors and not restricted to foregut neoplasms
36. Molecular genetics of neuroendocrine tumors
37. Alterations in the p161NK4a/CDKN2A tumor suppressor gene in gastrinomas
38. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: An analysis of p16/MTS1 tumor suppressor gene inactivation
39. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors
40. Deletion of chromosome 1 predicts prognosis in pancreatic endocrine tumors
41. A novel pancreatic endocrine tumor suppressor gene locus on chomosome 3p with clinical pronostic implications
42. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors
43. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling
44. Men in interacts with the AP1 transcription factor JunD and represses Jun D-activated transcription
45. High resolution allelotype of nonfunctional pancreatic endocrine tumors: Identification of two molecular subgroups with clinical implications